Deplano A, Denis O, Nonhoff C, Rost F, Byl B, Jacobs F, Vankerckhoven V, Goossens H, Struelens M J
Department of Microbiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
J Antimicrob Chemother. 2007 Oct;60(4):849-54. doi: 10.1093/jac/dkm270. Epub 2007 Jul 23.
To describe the investigation and molecular characterization of a vancomycin-resistant Enterococcus faecium (VREF) strain responsible for a nosocomial outbreak in the haematology unit of a tertiary-care university hospital.
Two patients admitted to the haematology unit developed infection/colonization with VREF over a 3 month period when compared with none in the 2 previous years. On the basis of the identification of a clonal link between these two strains, weekly rectal screening was implemented for all patients in the haematology unit and contact precautions were extended to VREF carriers. In the following 6 month period, 11 patients colonized with VREF were detected. No further case was detected in the following 1 year period.
VREF isolates from the haematology unit carried the vanA gene and were multiresistant to antimicrobial agents, including high-level resistance to vancomycin, teicoplanin and ampicillin. This resistance profile restricted the choice of antimicrobial therapy to linezolid or investigational drugs such as tigecycline. Molecular analysis showed that 11 of 13 (85%) VREF isolates belonged to pandemic clonal complex-17 carrying the esp and hyl virulence genes.
Rapid typing and infection control measures, including early reinforcement of barrier precautions combined with weekly rectal surveillance cultures, were followed by control of nosocomial spread of this VREF clone.
描述一株耐万古霉素屎肠球菌(VREF)的调查及分子特征,该菌株导致了一所三级大学医院血液科的医院感染暴发。
与前两年无人感染相比,血液科有两名患者在3个月内发生了VREF感染/定植。基于这两株菌株之间克隆联系的鉴定,对血液科所有患者实施每周一次的直肠筛查,并将接触预防措施扩大到VREF携带者。在接下来的6个月里,检测到11例VREF定植患者。在接下来的1年里未检测到更多病例。
血液科的VREF分离株携带vanA基因,对多种抗菌药物耐药,包括对万古霉素、替考拉宁和氨苄西林的高水平耐药。这种耐药情况限制了抗菌治疗的选择,只能使用利奈唑胺或诸如替加环素等试验性药物。分子分析显示,13株VREF分离株中有11株(85%)属于携带esp和hyl毒力基因的大流行克隆复合体-17。
快速分型和感染控制措施,包括早期加强屏障预防措施并结合每周直肠监测培养,随后控制了该VREF克隆的医院传播。